Frederick Carl Koerner, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 9 | 2009 | 480 | 1.240 |
Why?
|
| Carcinoma, Ductal, Breast | 10 | 2009 | 1097 | 0.860 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 12 | 2009 | 934 | 0.740 |
Why?
|
| Breast Neoplasms | 47 | 2015 | 21178 | 0.740 |
Why?
|
| Carcinoma in Situ | 7 | 2001 | 784 | 0.700 |
Why?
|
| Breast | 14 | 2014 | 1972 | 0.570 |
Why?
|
| Nipples | 5 | 2009 | 227 | 0.550 |
Why?
|
| Papilloma | 2 | 2010 | 143 | 0.530 |
Why?
|
| Carcinoma, Papillary | 5 | 2010 | 791 | 0.480 |
Why?
|
| Breast Diseases | 3 | 2004 | 441 | 0.390 |
Why?
|
| Hyperplasia | 5 | 2006 | 1150 | 0.360 |
Why?
|
| Carcinoma | 9 | 1998 | 2326 | 0.310 |
Why?
|
| Precancerous Conditions | 4 | 2006 | 980 | 0.260 |
Why?
|
| Fibrocystic Breast Disease | 2 | 2001 | 103 | 0.230 |
Why?
|
| Fibroadenoma | 2 | 2014 | 42 | 0.230 |
Why?
|
| Retinal Artery Occlusion | 1 | 2005 | 83 | 0.230 |
Why?
|
| Vitrectomy | 3 | 2005 | 392 | 0.220 |
Why?
|
| Receptors, Progesterone | 7 | 2001 | 1159 | 0.220 |
Why?
|
| Sialoglycoproteins | 2 | 2001 | 316 | 0.210 |
Why?
|
| Pathology, Surgical | 1 | 2004 | 147 | 0.200 |
Why?
|
| X-Ray Microtomography | 2 | 2015 | 456 | 0.200 |
Why?
|
| Receptors, Steroid | 1 | 2001 | 157 | 0.180 |
Why?
|
| Blindness | 1 | 2005 | 585 | 0.180 |
Why?
|
| Cystic Duct | 1 | 1999 | 18 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2005 | 523 | 0.170 |
Why?
|
| Mammary Glands, Human | 2 | 2014 | 201 | 0.160 |
Why?
|
| Cadherins | 2 | 2001 | 903 | 0.160 |
Why?
|
| Epithelium | 1 | 2004 | 1606 | 0.160 |
Why?
|
| Neuroendocrine Tumors | 2 | 1996 | 659 | 0.150 |
Why?
|
| Mastectomy, Subcutaneous | 2 | 2008 | 56 | 0.150 |
Why?
|
| Cyclin D1 | 3 | 1998 | 453 | 0.150 |
Why?
|
| Receptors, Estrogen | 8 | 2001 | 2252 | 0.150 |
Why?
|
| Macula Lutea | 1 | 1999 | 180 | 0.140 |
Why?
|
| Immunohistochemistry | 15 | 2006 | 11063 | 0.140 |
Why?
|
| Calcinosis | 3 | 2001 | 1481 | 0.140 |
Why?
|
| Ovary | 1 | 2001 | 965 | 0.140 |
Why?
|
| Vitreous Body | 1 | 1999 | 401 | 0.130 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 1996 | 29 | 0.130 |
Why?
|
| Neoplasm Proteins | 4 | 1998 | 3599 | 0.130 |
Why?
|
| Thrombolytic Therapy | 1 | 2005 | 2054 | 0.130 |
Why?
|
| Diagnosis, Differential | 9 | 2014 | 12986 | 0.130 |
Why?
|
| Phyllodes Tumor | 1 | 2014 | 55 | 0.110 |
Why?
|
| Lymphoid Tissue | 1 | 1996 | 445 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 1999 | 614 | 0.110 |
Why?
|
| Paraffin Embedding | 1 | 1994 | 303 | 0.100 |
Why?
|
| Microwaves | 1 | 1994 | 184 | 0.100 |
Why?
|
| Retinal Diseases | 1 | 1999 | 709 | 0.100 |
Why?
|
| Immunity, Mucosal | 1 | 1996 | 499 | 0.100 |
Why?
|
| Female | 58 | 2015 | 396660 | 0.100 |
Why?
|
| Mastectomy, Segmental | 2 | 2015 | 974 | 0.100 |
Why?
|
| Mastectomy | 3 | 2009 | 1861 | 0.090 |
Why?
|
| History, 19th Century | 2 | 2004 | 714 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 4 | 1998 | 2800 | 0.090 |
Why?
|
| Collagen | 2 | 1998 | 2636 | 0.090 |
Why?
|
| Stromal Cells | 2 | 2010 | 1335 | 0.090 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2005 | 111 | 0.090 |
Why?
|
| Keratins | 3 | 2006 | 499 | 0.090 |
Why?
|
| Microscopy, Electron | 5 | 1998 | 2551 | 0.080 |
Why?
|
| Middle Aged | 36 | 2015 | 223233 | 0.080 |
Why?
|
| Mammography | 6 | 2015 | 2431 | 0.080 |
Why?
|
| Osteopontin | 2 | 2001 | 305 | 0.080 |
Why?
|
| Humans | 64 | 2015 | 767040 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 3611 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 1997 | 6067 | 0.070 |
Why?
|
| Aged | 30 | 2015 | 171319 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 1998 | 3440 | 0.070 |
Why?
|
| Monitoring, Intraoperative | 1 | 2013 | 947 | 0.070 |
Why?
|
| In Situ Hybridization | 2 | 2001 | 1892 | 0.070 |
Why?
|
| Aged, 80 and over | 14 | 2015 | 59548 | 0.070 |
Why?
|
| Chromogranins | 2 | 1997 | 160 | 0.060 |
Why?
|
| History, 20th Century | 2 | 2004 | 2765 | 0.060 |
Why?
|
| Vitreous Detachment | 1 | 2005 | 23 | 0.060 |
Why?
|
| Tamoxifen | 2 | 2005 | 966 | 0.060 |
Why?
|
| Pseudophakia | 1 | 2005 | 61 | 0.060 |
Why?
|
| Aphakia, Postcataract | 1 | 2005 | 52 | 0.060 |
Why?
|
| Scleral Buckling | 1 | 2005 | 95 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2005 | 220 | 0.060 |
Why?
|
| Adult | 30 | 2015 | 223317 | 0.060 |
Why?
|
| Visual Acuity | 3 | 2005 | 2714 | 0.060 |
Why?
|
| Epithelial Cells | 3 | 2001 | 3698 | 0.060 |
Why?
|
| Cicatrix | 1 | 2010 | 798 | 0.060 |
Why?
|
| Cyclins | 2 | 1997 | 605 | 0.060 |
Why?
|
| Cytoplasm | 2 | 1999 | 1504 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2013 | 3552 | 0.050 |
Why?
|
| Proteins | 3 | 1992 | 6001 | 0.050 |
Why?
|
| Staining and Labeling | 2 | 2001 | 1076 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 13650 | 0.050 |
Why?
|
| Oncogene Proteins | 2 | 1997 | 715 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 1995 | 1697 | 0.050 |
Why?
|
| Eyelid Neoplasms | 2 | 2005 | 88 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2005 | 519 | 0.050 |
Why?
|
| Mucins | 2 | 1997 | 569 | 0.050 |
Why?
|
| Foam Cells | 1 | 2001 | 68 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2005 | 734 | 0.050 |
Why?
|
| Genes, RAG-1 | 1 | 2001 | 68 | 0.050 |
Why?
|
| Retinal Detachment | 1 | 2005 | 429 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 1999 | 2875 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 4052 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2001 | 748 | 0.040 |
Why?
|
| Epiretinal Membrane | 1 | 1999 | 73 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2005 | 1090 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1998 | 317 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2001 | 581 | 0.040 |
Why?
|
| Species Specificity | 1 | 2001 | 2412 | 0.030 |
Why?
|
| Retrospective Studies | 11 | 2014 | 81659 | 0.030 |
Why?
|
| Hemosiderin | 1 | 1996 | 41 | 0.030 |
Why?
|
| Silver Staining | 1 | 1996 | 63 | 0.030 |
Why?
|
| Synaptophysin | 1 | 1996 | 138 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 1998 | 630 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1997 | 697 | 0.030 |
Why?
|
| Smooth Muscle Tumor | 1 | 1996 | 65 | 0.030 |
Why?
|
| Sensitivity and Specificity | 4 | 2008 | 14672 | 0.030 |
Why?
|
| DNA, Protozoan | 1 | 1996 | 227 | 0.030 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 1996 | 260 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 2079 | 0.030 |
Why?
|
| Antibodies, Protozoan | 1 | 1996 | 251 | 0.030 |
Why?
|
| Toxoplasma | 1 | 1996 | 159 | 0.030 |
Why?
|
| Adipocytes | 1 | 2001 | 1197 | 0.030 |
Why?
|
| Microtomy | 1 | 1994 | 44 | 0.030 |
Why?
|
| Organelles | 1 | 1996 | 265 | 0.030 |
Why?
|
| Acute Disease | 1 | 2005 | 7236 | 0.030 |
Why?
|
| Melanocytes | 1 | 1997 | 509 | 0.030 |
Why?
|
| Vulvar Neoplasms | 1 | 1996 | 266 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 1623 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1998 | 1074 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1997 | 542 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 3488 | 0.030 |
Why?
|
| Syndrome | 1 | 1999 | 3271 | 0.030 |
Why?
|
| Lymphatic Metastasis | 4 | 2013 | 2900 | 0.020 |
Why?
|
| Treatment Outcome | 5 | 2013 | 65295 | 0.020 |
Why?
|
| Granular Cell Tumor | 1 | 1992 | 48 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 1994 | 959 | 0.020 |
Why?
|
| Fluoxymesterone | 1 | 1991 | 12 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2001 | 2429 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1991 | 128 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2001 | 2843 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2001 | 4167 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 1998 | 9410 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2014 | 41718 | 0.020 |
Why?
|
| Silver | 1 | 1991 | 119 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1991 | 338 | 0.020 |
Why?
|
| Doxorubicin | 2 | 2013 | 2229 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 2 | 1994 | 4522 | 0.020 |
Why?
|
| Progesterone | 1 | 1994 | 752 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 1992 | 574 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1997 | 1383 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1997 | 1061 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1989 | 321 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1233 | 0.020 |
Why?
|
| Observer Variation | 1 | 2014 | 2616 | 0.020 |
Why?
|
| Calcium | 1 | 2001 | 5792 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 1012 | 0.020 |
Why?
|
| Adolescent | 5 | 2014 | 89046 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2008 | 153 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2013 | 8732 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1994 | 1441 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2008 | 614 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2005 | 22254 | 0.020 |
Why?
|
| Mucin-1 | 1 | 1991 | 536 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1994 | 1540 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2001 | 12793 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2013 | 1728 | 0.020 |
Why?
|
| Cheek | 1 | 2005 | 66 | 0.020 |
Why?
|
| Animals | 4 | 2001 | 168965 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1996 | 4560 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 24299 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2008 | 706 | 0.010 |
Why?
|
| Pregnancy | 3 | 2001 | 30238 | 0.010 |
Why?
|
| Suture Techniques | 1 | 2008 | 775 | 0.010 |
Why?
|
| Male | 8 | 2005 | 364203 | 0.010 |
Why?
|
| Neoplasm Metastasis | 2 | 1991 | 4892 | 0.010 |
Why?
|
| Child | 3 | 2001 | 80771 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6844 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 11872 | 0.010 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 39317 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 2902 | 0.010 |
Why?
|
| Postoperative Complications | 2 | 2005 | 15824 | 0.010 |
Why?
|
| Disease Progression | 1 | 1998 | 13646 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1991 | 3702 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1990 | 1481 | 0.010 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2001 | 256 | 0.010 |
Why?
|
| DNA, Neoplasm | 2 | 1995 | 1741 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2008 | 6331 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1995 | 8628 | 0.010 |
Why?
|
| Karyotyping | 1 | 2001 | 1176 | 0.010 |
Why?
|
| Genes, ras | 1 | 2001 | 656 | 0.010 |
Why?
|
| Prognosis | 3 | 1994 | 29963 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1994 | 15424 | 0.010 |
Why?
|
| Young Adult | 2 | 2014 | 59980 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2001 | 549 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 4256 | 0.010 |
Why?
|
| Metaplasia | 1 | 1997 | 326 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2008 | 54886 | 0.010 |
Why?
|
| Time Factors | 1 | 1998 | 40154 | 0.010 |
Why?
|
| Neoplasm Staging | 4 | 1992 | 11217 | 0.010 |
Why?
|
| Risk Factors | 3 | 2014 | 74886 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2001 | 1615 | 0.010 |
Why?
|
| Telomerase | 1 | 2001 | 751 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1997 | 1550 | 0.010 |
Why?
|
| Melanoma | 1 | 1994 | 5702 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2001 | 2509 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1986 | 3468 | 0.010 |
Why?
|
| ROC Curve | 1 | 2001 | 3618 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1997 | 1989 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 4473 | 0.010 |
Why?
|
| S Phase | 1 | 1994 | 424 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2001 | 2391 | 0.010 |
Why?
|
| Leiomyosarcoma | 1 | 1996 | 426 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1997 | 1103 | 0.010 |
Why?
|
| Myoglobin | 1 | 1992 | 158 | 0.010 |
Why?
|
| Leiomyoma | 1 | 1996 | 644 | 0.010 |
Why?
|
| Receptor, erbB-2 | 2 | 1994 | 2599 | 0.010 |
Why?
|
| S100 Proteins | 1 | 1992 | 216 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 9464 | 0.010 |
Why?
|
| Biopsy | 2 | 1995 | 6777 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1997 | 1500 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1997 | 6106 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1989 | 816 | 0.000 |
Why?
|
| Fluorouracil | 1 | 1994 | 1652 | 0.000 |
Why?
|
| Prevalence | 1 | 2005 | 15851 | 0.000 |
Why?
|
| Cyclophosphamide | 1 | 1994 | 2227 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1995 | 5022 | 0.000 |
Why?
|
| Survival Rate | 2 | 1992 | 12823 | 0.000 |
Why?
|
| Base Sequence | 1 | 1997 | 12414 | 0.000 |
Why?
|
| Gastrectomy | 1 | 1990 | 693 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 2001 | 14476 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1997 | 13411 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 2 | 1994 | 9245 | 0.000 |
Why?
|
| Abdomen | 1 | 1990 | 1138 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 17608 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 7611 | 0.000 |
Why?
|
| Postoperative Care | 1 | 1989 | 1480 | 0.000 |
Why?
|
| Survival Analysis | 1 | 1994 | 10092 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1997 | 11657 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1990 | 8535 | 0.000 |
Why?
|
| Lymphoma | 1 | 1987 | 1896 | 0.000 |
Why?
|
| Massachusetts | 1 | 1990 | 8890 | 0.000 |
Why?
|
| Radiography | 1 | 1987 | 6975 | 0.000 |
Why?
|
| Age Factors | 1 | 1992 | 18401 | 0.000 |
Why?
|
| Mice | 1 | 2001 | 81912 | 0.000 |
Why?
|